MicroRNA-29 negatively regulates EMT regulator N-myc interactor in breast cancer

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Rostas, Jack W ^b   Pruitt, Hawley C ^a   Metge, Brandon J ^a   Mitra, Aparna ^c   Bailey, Sarah K ^a   Bae, Sejong ^d,e   Singh, Karan P ^d,e   Devine, Daniel J ^c   Dyess, Donna L ^b   Richards, William O ^b   Tucker, J A ^b   Shevde, Lalita A ^a,e   Samant, Rajeev S ^a,e  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTH ALABAMA   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Breast cancer; EMT; miR 29; N Myc interactor

Indexed keywords

BETA CATENIN; MESSENGER RNA; MICRORNA; MICRORNA 29; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; GSK3B PROTEIN, HUMAN; MIRN29 MICRORNA, HUMAN; NMI PROTEIN, HUMAN; SIGNAL PEPTIDE;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LUCIFERASE ASSAY; METASTASIS; ONCOGENE C MYB; OSTEOBLAST; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ALGORITHM; BIOLOGY; BREAST TUMOR; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENETICS; MCF-7 CELL LINE; METABOLISM; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

ALGORITHMS; BREAST NEOPLASMS; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MCF-7 CELLS; MICRORNAS; NEOPLASM INVASIVENESS; SIGNAL TRANSDUCTION;

EID: 84907407143     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-200     Document Type: Article

References (54)

1. Bao J, Zervos AS. Isolation and characterization of Nmi, a novel partner of Myc proteins. Oncogene 1996, 12:2171-2176.
2. Bannasch D, Weis I, Schwab M. Nmi protein interacts with regions that differ between MycN and Myc and is localized in the cytplasm of neuroblastoma cells in contrast to nuclear MycN. Oncogene 1999, 18:6810-6817. 10.1038/sj.onc.1203090, 10597290.
3. Zhu M, Susan J, Maria B, Leonard WJ. Functional Association of Nmi with Stat5 and Stat1 in IL-2- and IFNγ-mediated signaling. Cell 1999, 96:121-130. 10.1016/S0092-8674(00)80965-4, 9989503.
4. Li H, Tae-Hee L, Hava A. A novel tricomplex of BRCA1, Nmi, and c-Myc Inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer. J Biol Chem 2002, 277:20965-20973. doi:10.1074/jbc.M112231200, 10.1074/jbc.M112231200, 11916966.
5. Schlierf B, Lang S, Kosian T, Werner T, Wegner M. The high-mobility group transcription factor Sox10 interacts with the N-myc-interacting protein Nmi. J Mol Biol 2005, 353:1033-1042. doi:10.1016/j.jmb.2005.09.013, 10.1016/j.jmb.2005.09.013, 16214168.
6. Zhang K, Zheng G, Yang Y. Stability of Nmi protein is controlled by its association with Tip60. Mol Cell Biol 2007, 303:1-8. doi:10.1007/s11010-007-9449-y.
7. Li Z, Hou J, Sun L, Wen T, Wang L, Zhao X, Xie Q, Zhang SQ. NMI mediates transcription-independent ARF regulation in response to cellular stresses. Mol Biol Cell 2012, 23:4635-4646. doi:10.1091/mbc.E12-04-0304, 10.1091/mbc.E12-04-0304, 3510024, 23034180.
8. Devine DJ, Rostas JW, Metge BJ, Das S, Mulekar MS, Tucker JA, Grizzle WE, Buchsbaum DJ, Shevde LA, Samant RS. Loss of N-Myc interactor promotes epithelial-mesenchymal transition by activation of TGF-beta/SMAD signaling. Oncogene 2013, doi:10.1038/onc.2013.215.
9. Fillmore RA, Mitra A, Xi Y, Ju J, Scammell J, Shevde LA, Samant RS. Nmi (N-Myc interactor) inhibits Wnt/β-catenin signaling and retards tumor growth. Int J Cancer 2009, 125:556-564. 10.1002/ijc.24276, 19358268.
10. Lovat F, Valeri N, Croce CM. MicroRNAs in the pathogenesis of cancer. Semin Oncol 2011, 38:724-733. doi:10.1053/j.seminoncol.2011.08.006, 10.1053/j.seminoncol.2011.08.006, 22082758.
11. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010, 31:27-36. doi:10.1093/carcin/bgp220, 10.1093/carcin/bgp220, 2802667, 19752007.
12. Huynh KT, Hoon DS. Epigenetics of regional lymph node metastasis in solid tumors. Clin Exp Metastas 2012, 29:747-756. doi:10.1007/s10585-012-9491-3.
13. Fabian MR, Sundermeier TR, Sonenberg N. Understanding how miRNAs post-transcriptionally regulate gene expression. Prog Mol Subcell Biol 2010, 50:1-20. doi:10.1007/978-3-642-03103-8_1, 10.1007/978-3-642-03103-8_1, 19841878.
14. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297. 10.1016/S0092-8674(04)00045-5, 14744438.
15. Yu Z, Pestell RG. Small non-coding RNAs govern mammary gland tumorigenesis. J Mammary Gland Biol Neoplasia 2012, 17:59-64. doi:10.1007/s10911-012-9246-4, 10.1007/s10911-012-9246-4, 3309138, 22382486.
16. Piao HL, Ma L. Non-coding RNAs as regulators of mammary development and breast cancer. J Mammary Gland Biol Neoplasia 2012, 17:33-42. doi:10.1007/s10911-012-9245-5, 10.1007/s10911-012-9245-5, 3686545, 22350981.
17. Valastyan S. Roles of microRNAs and other non-coding RNAs in breast cancer metastasis. J Mammary Gland Biol Neoplasia 2012, 17:23-32. doi:10.1007/s10911-012-9241-9, 10.1007/s10911-012-9241-9, 22293951.
18. Lewis BP BC, Bartel DP. 2005, http://www.targetscan.org/.
19. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20. doi:10.1016/j.cell.2004.12.035, 10.1016/j.cell.2004.12.035, 15652477.
20. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human MicroRNA targets. PLoS Biol 2005, 3(7):e264. doi:10.1371/journal.pbio.0020363.
21. John B, Sander C, Marks DS. Prediction of human microRNA targets. Methods Mol Biol 2006, 342:101-113. doi:10.1385/1-59745-123-1:101.
22. Xiaowei Wang's lab at the Department of Radiation Oncology, W. U. S. o. M. i. S. L 2012, http://mirdb.org/miRDB/, Xiaowei Wang's lab at the Department of Radiation Oncology, W. U. S. o. M. i. S. L.
23. Wang X. miRDB: a microRNA target prediction and functional annotation database with a wiki interface. RNA 2008, 14:1012-1017. doi:10.1261/rna.965408, 10.1261/rna.965408, 2390791, 18426918.
24. Wang X, El Naqa IM. Prediction of both conserved and nonconserved microRNA targets in animals. Bioinformatics 2008, 24:325-332. doi:10.1093/bioinformatics/btm595, 10.1093/bioinformatics/btm595, 18048393.
25. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003, 30:256-268. 10.1016/S1046-2023(03)00032-X, 12798140.
26. Debnath J, Brugge JS. Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 2005, 5:675-688. doi:10.1038/nrc1695, 10.1038/nrc1695, 16148884.
27. Menezes ME, Mitra A, Shevde LA, Samant RS. DNAJB6 governs a novel regulatory loop determining Wnt/beta-catenin signalling activity. Biochem J 2012, 444:573-580. doi:10.1042/BJ20120205, 10.1042/BJ20120205, 3712349, 22455953.
28. Mitra A, Fillmore RA, Metge BJ, Rajesh M, Xi Y, King J, Ju J, Pannell L, Shevde LA, Samant RS. Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer. Breast Cancer Res 2008, 10:R22. doi:10.1186/bcr1874, 10.1186/bcr1874, 2397520, 18328103.
29. Yang H, Cho ME, Li TW, Peng H, Ko KS, Mato JM, Lu SC. MicroRNAs regulate methionine adenosyltransferase 1A expression in hepatocellular carcinoma. J Clin Investig 2013, 123:285-298. doi:10.1172/JCI63861, 10.1172/JCI63861, 3533284, 23241961.
30. Prazeres H, Torres J, Rodrigues F, Pinto M, Pastoriza MC, Gomes D, Cameselle-Teijeiro J, Vidal A, Martins TC, Sobrinho-Simoes M, Soares P. Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells. Oncogene 2011, 30:1302-1317. doi:10.1038/onc.2010.512, 10.1038/onc.2010.512, 21057533.
31. Heyn H, Schreek S, Buurman R, Focken T, Schlegelberger B, Beger C. MicroRNA miR-548d is a superior regulator in pancreatic cancer. Pancreas 2012, 41:218-221. doi:10.1097/MPA.0b013e318224b701, 10.1097/MPA.0b013e318224b701, 21946813.
32. Han YC, Park CY, Bhagat G, Zhang J, Wang Y, Fan JB, Liu M, Zou Y, Weissman IL, Gu H. microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. J Exp Med 2010, 207:475-489. doi:10.1084/jem.20090831, 10.1084/jem.20090831, 2839143, 20212066.
33. Gebeshuber CA, Zatloukal K, Martinez J. miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep 2009, 10:400-405. doi:10.1038/embor.2009.9, 10.1038/embor.2009.9, 2672883, 19247375.
34. Kim JW, Mori S, Nevins JR. Myc-induced microRNAs integrate Myc-mediated cell proliferation and cell fate. Cancer Res 2010, 70:4820-4828. doi:10.1158/0008-5472.CAN-10-0659, 10.1158/0008-5472.CAN-10-0659, 2888768, 20516112.
35. Boggs RM, Wright ZM, Stickney MJ, Porter WW, Murphy KE. MicroRNA expression in canine mammary cancer. Mamm Genome 2008, 19:561-569. doi:10.1007/s00335-008-9128-7, 10.1007/s00335-008-9128-7, 18665421.
36. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005, 65:7065-7070. doi:10.1158/0008-5472.CAN-05-1783, 10.1158/0008-5472.CAN-05-1783, 16103053.
37. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R, Haqq C. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 2006, 5:24. doi:10.1186/1476-4598-5-24, 10.1186/1476-4598-5-24, 1563474, 16784538.
38. Chen GQ, Zhao ZW, Zhou HY, Liu YJ, Yang HJ. Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin. Med Oncol 2010, 27:406-415. doi:10.1007/s12032-009-9225-9, 10.1007/s12032-009-9225-9, 19412672.
39. Kapinas K, Kessler C, Ricks T, Gronowicz G, Delany AM. miR-29 modulates Wnt signaling in human osteoblasts through a positive feedback loop. J Biol Chem 2010, 285:25221-25231. doi:10.1074/jbc.M110.116137, 10.1074/jbc.M110.116137, 2919085, 20551325.
40. Kapinas K, Kessler CB, Delany AM. miR-29 suppression of osteonectin in osteoblasts: regulation during differentiation and by canonical Wnt signaling. J Cell Biochem 2009, 108:216-224. doi:10.1002/jcb.22243, 10.1002/jcb.22243, 2888144, 19565563.
41. Lee CC, Chen WS, Chen CC, Chen LL, Lin YS, Fan CS, Huang TS. TCF12 protein functions as transcriptional repressor of E-cadherin, and its overexpression is correlated with metastasis of colorectal cancer. J Biol Chem 2012, 287:2798-2809. doi:10.1074/jbc.M111.258947, 10.1074/jbc.M111.258947, 3268437, 22130667.
42. Consortium EP. A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol 2011, 9:e1001046. doi:10.1371/journal.pbio.1001046, 10.1371/journal.pbio.1001046, 3079585, 21526222.
43. Rosenbloom KR, Sloan CA, Malladi VS, Dreszer TR, Learned K, Kirkup VM, Wong MC, Maddren M, Fang R, Heitner SG, Lee BT, Barber GP, Harte RA, Diekhans M, Long JC, Wilder SP, Zweig AS, Karolchik D, Kuhn RM, Haussler D, Kent WJ. ENCODE data in the UCSC Genome Browser: year 5 update. Nucleic Acids Res 2013, 41:D56-63. doi:10.1093/nar/gks1172, 10.1093/nar/gks1172, 3531152, 23193274.
44. Li S, Sun Y, Li L. The expression of beta-catenin in different subtypes of breast cancer and its clinical significance. Tumour Biol 2014, doi:10.1007/s13277-014-1975-0.
45. Dey N, Young B, Abramovitz M, Bouzyk M, Barwick B, De P, Leyland-Jones B. Differential activation of Wnt-beta-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner. PLoS ONE 2013, 8:e77425. doi:10.1371/journal.pone.0077425, 10.1371/journal.pone.0077425, 3797090, 24143235.
46. Incassati A, Chandramouli A, Eelkema R, Cowin P. Key signaling nodes in mammary gland development and cancer: beta-catenin. Breast Cancer Res 2010, 12:213. doi:10.1186/bcr2723, 10.1186/bcr2723, 3046427, 21067528.
47. Mukherjee N, Bhattacharya N, Alam N, Roy A, Roychoudhury S, Panda CK. Subtype-specific alterations of the Wnt signaling pathway in breast cancer: clinical and prognostic significance. Cancer Sci 2012, 103:210-220. doi:10.1111/j.1349-7006.2011.02131.x, 10.1111/j.1349-7006.2011.02131.x, 22026417.
48. Menezes ME, Devine DJ, Shevde LA, Samant RS. Dickkopf1: a tumor suppressor or metastasis promoter?. Int J Cancer 2012, 130:1477-1483. doi:10.1002/ijc.26449, 10.1002/ijc.26449, 3253198, 21953410.
49. Inui M, Montagner M, Piccolo S. miRNAs and morphogen gradients. Curr Opin Cell Biol 2012, 24:194-201. doi:10.1016/j.ceb.2011.11.013, 10.1016/j.ceb.2011.11.013, 22196932.
50. Jiang H, Zhang G, Wu JH, Jiang CP. Diverse roles of miR-29 in cancer (Review). Oncol Rep 2014, doi:10.3892/or.2014.3036.
51. Park SY, Lee JH, Ha M, Nam JW, Kim VN. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 2009, 16:23-29. doi:10.1038/nsmb.1533, 10.1038/nsmb.1533, 19079265.
52. Chou J, Lin JH, Brenot A, Kim JW, Provot S, Werb Z. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat Cell Biol 2013, 15:201-213. doi:10.1038/ncb2672, 10.1038/ncb2672, 3660859, 23354167.
53. Wang C, Bian Z, Wei D, Zhang JG. miR-29b regulates migration of human breast cancer cells. Mol Cell Biochem 2011, 352:197-207. doi:10.1007/s11010-011-0755-z, 10.1007/s11010-011-0755-z, 21359530.
54. Santanam U, Zanesi N, Efanov A, Costinean S, Palamarchuk A, Hagan JP, Volinia S, Alder H, Rassenti L, Kipps T, Croce CM, Pekarsky Y. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci U S A 2010, 107:12210-12215. doi:10.1073/pnas.1007186107, 10.1073/pnas.1007186107, 2901490, 20566844.